MASCC

Multinational Association of supportive Care in Cancer www.mascc.org

National Cancer Institute

www.cancer.gov

National Health Service UK

www.nhs.uk

UKOMiC

UK Oral Mucositis in Cancer Group www.ukomic.co.uk

EOCC

European Oral Care in Cancer Group
Oral Care Guidance and Support
www.cancernurse.eu

REFERENCES

  1. Sonis, S. T. (2004) Oral mucositis in cancer therapy. J Support Oncology, 2(3):3–8.
  2. Trotti, A., Bellm, L. A., Epstein, J. B., et al. (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol, 66(3):253–262.
  3. Wardley, A. M., Jayson, G. C., Swindell, R., et al. (2000) Prospective evaluation of OM in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol, 110(2):292–299.
  4. Fulton, J. S., Middleton, G. J., McPhail, J. T. (2002) Management of oral complications. Semin Oncol Nurs, 18(1):28–35.
  5. Dodd, M. J., Miaskowski, C., Dibble, S. L., et al. (2000) Factors influencing OM in patients receiving chemotherapy. Cancer Pract, 8(6):291–297.
  6. Vera-Llonch, M., Oster, G., et al. (2006) Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer, 106(2):329–336.
  7. Bruce, S. D., Quinn, A. (2007) US Oncological Disease, 1:86–90.
  8. Barauskas, J., Christerson, L., Wadsäter, M., et al, (2014) Bioadhesive Lipid Compositions: Self-Assembly Structures, Functionality, and Medical Applications. Mol. Pharmaceutics, 11(3):895−903.
  9. Camurus. (2017) episil® package leaflet.
  10. Seidenspinner, I., Adamietz, I. A., Strohm, G. L. and Tiberg, F. (2015) Effects of episil® oral liquid in cancer patients with oral mucositis: an observational study. Poster presented at MASCC, 2015.
  11. Hadjieva, T., Cavallin-Ståhl, E., Linden, M. and Tiberg, F. (2014) Treatment of oral mucositis pain following radiation therapy for head-and-neck cancer using a bioadhesive barrier-forming lipid solution. Support Care Cancer, 22(6):1557–1562.
  12. Patent EP1848403. Topical Bioadhesive Formulations.
  13. Svanberg, A., Birgegård, G., Öhrn, K. (2010) A new preventive strategy using a bioadhesive oromucosal lipid solution and oral cryotherapy to protect the oral cavity and reduce the need for total parenteral nutrition (TPN) for patients undergoing autologous stemcell transplantation. Support Care Cancer, 18, (Suppl. 3) S114.
  14. Cheng Y., Qin S.K., Chen Y.P., et al. (2018) Local analgesic effect of a bioadhesive barrier-forming oral liquid in cancer patients with oral mucositis caused by chemotherapy and/or radiotherapy: a randomised, multicenter, single-use, positive-controlled, open-label study. Onco Targets Ther. 11: 8555-8564
  15. Wei J., Wu J., Wang H., et al. (2021) A bioadhesive barrier-forming oral liquid gel improved oral mucositis and nutritional status in patients with head and neck cancers undergoing radiotherapy: A retrospective single center study, Front. Oncol., 11: 617392.